Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME

  • End date
    Sep 30, 2021
  • participants needed
  • sponsor
    Beijing Hospital
Updated on 23 January 2021
type 2 diabetes mellitus
hemoglobin a1c
glycosylated hemoglobin
diabetic retinopathy


The objective of this study is to evaluate if combination of intravitreal ranibizumab with micropulse laser shows non inferiority compared to intravitreal ranibizumab only in diabetic macular edema.


To investigate the efficacy of intravitreal ranibizumab injections compared to combination with Micropulse Laser in Chinese patients with visual impairment in DME.

The result of the study will be used to support new therapy in DME patients in China.

Condition Diabetic Macular Edema
Treatment Micropulse Laser, intravitreal ranibizumab, Intravitreal Ranibizumab as needed
Clinical Study IdentifierNCT03690947
SponsorBeijing Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Informed consent form must be signed before any tests or procedures are done
Male or female of 30 to 80 years of age (inclusive) at the first screening visit
Diagnosis of type 2 diabetes, with fasting blood glucose10mmol/L, HbA1C10.0%
Diabetic medication must be stable for at least 3 months before first screening visit and remain stable during study
Diagnosis of non-proliferative diabetic retinopathy with diabetic macular edema resulting in visual acuity reduction
Study eye's BCVA between 24 to 78 ETDRS letters at screening and baseline of the study
Macular edema of the study eye and central retinal thickness 300 m determined by SD-OCT
Study eye had not had grid pattern photocoagulation, intraocular surgery, intravitreal corticosteroid injections and intravitreal anti-VEGF injections for at least 3 months before baseline
Non-study eye's BCVA 24 ETDRS letters at screening and baseline of the study
Non-study eye had not had intravitreal anti-VEGF injections for at least 3 months before baseline
If both eyes qualify, then investigators will choose an eye with worse BCVA as study eye. Only study eye will receive intravitreal ranibizumab and/or Micropulse Laser treatment

Exclusion Criteria

Failure to follow study or follow-up procedures
Pregnant or breast-feeding woman and woman without adequate method of contraception
History of stroke or myocardial infarction within 3 months before screening
Renal failure or creatinine > 2.0 mg/dl
Uncontrolled systemic diseases or systemic treatment that may affect results of the study
Active ocular or intraocular infections of either eye
Neovascularization of the iris or neovascular glaucoma of either eye
A history of uveitis or vitreous macular traction in study eye
Glaucoma or IOP24 mmHg of study eye
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note